Stockreport

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]

Harrow Health, Inc.  (HROW) 
Last harrow health, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow's transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable su [Read more]